Amgen (AMGN) Reports Publication of Data from Two Evolocumab Phase 3s
Tweet Send to a Friend
Amgen (Nasdaq: AMGN) announced The Lancet published data from two Phase 3 studies, RUTHERFORD-2 and TESLA, that showed treatment with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
